SZ 004
Alternative Names: SZ-004Latest Information Update: 28 Aug 2024
At a glance
- Originator Sarfez Pharmaceuticals
- Class Antihyperglycaemics; Heart failure therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Heart failure
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
- 28 Aug 2024 No recent reports of development identified for preclinical development in Heart-failure in USA
- 01 Jul 2020 Preclinical trials in Diabetes mellitus in USA (unspecified route), prior to July 2020 (Sarfez Pharmaceuticals pipeline, July 2020)